1. Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007; 57:1–27.
Article
2. Gupta AK, Cooper EA. Psoriatic nail disease: quality of life and treatment. J Cutan Med Surg. 2009; 13:Suppl 2. S102–S106.
Article
3. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005; 366:1367–1374.
Article
4. Rich P, Bourcier M, Sofen H, Fakharzadeh S, Wasfi Y, Wang Y, et al. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. Br J Dermatol. 2014; 170:398–407.
Article
5. Thaçi D, Unnebrink K, Sundaram M, Sood S, Yamaguchi Y. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study. J Eur Acad Dermatol Venereol. 2015; 29:353–360.
Article
6. Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003; 49:206–212.
Article
7. Neerja Puri BBM. Nail changes in psoriasis - A profile. J Pakistan Assoc Dermatol. 2011; 21:165–169.
8. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001; 137:280–284.
9. Youn SW, Kim BR, Lee JH, Song HJ, Choe YB, Choi JH, et al. Comparison of treatment goals for moderate-to-severe psoriasis between korean dermatologists and the European consensus report. Ann Dermatol. 2015; 27:184–189.
Article
10. Reich K. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol. 2009; 23:Suppl 1. 15–21.
Article
11. Van den Bosch F, Manger B, Goupille P, McHugh N, Rødevand E, Holck P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis. 2010; 69:394–399.
Article
12. Barrera MV, Habicheyn S, Mendiola MV, Herrera Ceballos E. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice. Eur J Dermatol. 2008; 18:683–687.
13. Rallis E, Kintzoglou S, Verros C. Ustekinumab for rapid treatment of nail psoriasis. Arch Dermatol. 2010; 146:1315–1316.
Article
14. Patsatsi A, Kyriakou A, Sotiriadis D. Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study. J Dermatolog Treat. 2013; 24:96–100.
Article
15. Tan AL, Benjamin M, Toumi H, Grainger AJ, Tanner SF, Emery P, et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis--a high-resolution MRI and histological study. Rheumatology (Oxford). 2007; 46:253–256.
Article